# Ingenium Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/ingenium-therapeutics

- Industry: Biotechnology
- Headquarters: South Korea
- Website: www.ingeniumcell.co.kr
- Total disclosed funding: $0.9M
- Latest round: Seed (Dec 12, 2023)
- Investors on record: 2

## About

Based in Deajeon, South Korea, and founded in 2020 by CEO Jinok Koh, and CTO Sangyong Kim, Ingenium Therapeutics Co., Ltd. is a treatment development company that specializes in the development of anti-cancer cell therapy and related immuno-oncology drugs. The company researches NK cells to develop NK anti-cancer immunotherapy. In April 2021, Ingenium Therapeutics Co., Ltd. raised KRW 5.7 billion in pre-series A funding from Kairos Investment, KGround Ventures, Laplace Partners Inc., and Maple Investment Partners.

The company provides NK cell-based next-generation anti-cancer immune cell therapy for the treatment of patients suffering from refractory acute myeloid leukemia (refractory AML).

Ingenium Therapeutics plans to conduct a global clinical trial in 2023.

## Funding rounds

- Seed, Dec 12, 2023, $0.9M — Capstone Partners, Korea Tech Incubator for Startup

## Investors

- Capstone Partners (https://capitalatlas.ai/funds/capstone-partners) — Seed
- Korea Tech Incubator for Startup — Seed